Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
CYCLIZINE HYDROCHLORIDE
Amdipharm Limited
R06AE; R06AE03
CYCLIZINE HYDROCHLORIDE
50 milligram(s)
Tablet
Product subject to prescription which may not be renewed (A)
Piperazine derivatives; cyclizine
Marketed
1979-04-01
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT VALOID® 50 MG TABLETS (cyclizine hydrochloride) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. This medicine has been prescribed for you only. Do not pass it to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. The name of your medicine is Valoid 50 mg Tablets. It will be referred to as Valoid Tablets for ease hereafter. WHAT IS IN THIS LEAFLET 1. What Valoid Tablets are and what they are used for 2. What you need to know before you take Valoid Tablets 3. How to take Valoid Tablets 4. Possible side effects 5. How to store Valoid Tablets 6. Contents of the pack and other information 1. WHAT VALOID TABLETS ARE AND WHAT THEY ARE USED FOR Each tablet contains 50 mg of the active ingredient, cyclizine hydrochloride. Valoid Tablets belongs to a group of medicines called antihistamines. These are used in adults and children aged over 6 years to block the effects of substances called histamine and acetylcholine in your body, which can make you feel sick (nausea) or actually vomit. Valoid Tablets are used for travel or motion sickness, and nausea which can be caused by radiotherapy or some medicines. Some ear disorders, for example Meniere’s disease, can cause loss of balance. Valoid Tablets are used to treat the dizziness and vomiting which can come with this. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE VALOID TABLETS DO NOT TAKE VALOID TABLETS IF YOU: are allergic to cyclizine hydrochloride or any of the other ingredients of this medicine (listed in section 6). Allergic reactions include mild symptoms such as itching and / or rash. More severe symptoms include swelling of the fac Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Valoid 50 mg Tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 50mg of cyclizine hydrochloride. Excipient with known effect: Lactose (60mg/tablet) For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet. White, biconvex, uncoated tablet, scored; coded T4A. The scoreline is to facilitate breaking for ease of swallowing and to divide into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Valoid is indicated in adults and children aged 6 years and over for the prevention and treatment of nausea and vomiting, including: Motion sickness. Nausea and vomiting caused by narcotic analgesics and by general anaesthetics in the post-operative period. Vomiting associated with radiotherapy, especially for breast cancer since cyclizine does not elevate prolactin levels. Valoid may be of value in relieving vomiting and attacks of vertigo associated with Meniere's disease and other forms of vestibular disturbance. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology To prevent motion sickness Valoid Tablets should be taken about one to two hours before departure. _Elderly_ There have been no specific studies of Valoid Tablets in the elderly. Experience has indicated that normal adult dosage is appropriate. _Paediatric population_ Children less than 6 years of age: Valoid Tablets are not recommended for children less than 6 years of age. Children 6 to 12 years of age: 25 mg orally, which may be repeated up to three times a day. Children over 12 years of age: 50 mg orally, which may be repeated up to three times a day. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ Read the complete document